Link to article at PubMed

2022 Feb 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–.


Linaclotide is an orally administered medication with a once-a-day dosage regimen and a first-in-class, potent, and highly selective agonist of guanylate cyclase-C (GC-C) receptors in the inner lining of the intestine. This therapeutic peptide has negligible bioavailability following oral administration and a favorable safety profile. In the USA, the FDA approved it on 30th August 2012 for the treatment of adults suffering from the following medical conditions.

PMID:35201736 | Bookshelf:NBK578208

Leave a Reply

Your email address will not be published.